Divi's Laboratories Limited (DIVISLAB) — Financial Results | 7 August 2025

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Divi's Laboratories Limited disclosed unaudited financial results for Q1 FY2026 (quarter ended June 30, 2025) through newspaper publications on August 7, 2025. The filing is a regulatory notification submitting newspaper clippings of results to NSE and BSE as per SEBI listing requirements. Specific financial metrics and performance data are referenced in the newspaper publications but not detailed in this regulatory cover letter.

📄 View Original Announcement (PDF)

About Divi's Laboratories Limited (DIVISLAB)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,79,470.03 Cr P/E: 72.4 ROE: 16.6% ROCE: 22.1%

View full DIVISLAB stock details →

📡 Get AI alerts when DIVISLAB files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DIVISLAB — Free

📊 More DIVISLAB filings

See all DIVISLAB filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DIVISLAB files new disclosures

Track DIVISLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track DIVISLAB — Free

Free account · 2 AI queries/day